zorevunersen
Nucleic acidexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jun 4, 2025 (NCT06872125)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Sodium channel protein type I alpha subunitANTISENSE INHIBITOR
SCN1A antisense inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095386 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06872125 | Phase 3 | Jun 4, 2025 | Stoke Therapeutics, Inc |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Stoke Therapeutics, Inc | For profit | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1